Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2008-03-19
2010-12-07
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C514S002600, C424S085400
Reexamination Certificate
active
07846447
ABSTRACT:
The pharmaceutical composition is useful for treating epithelial tumors in a subject and contains at least two antigens and a pharmaceutically acceptable carrier, where each of the antigens induces or is capable of inducing a cutaneous delayed type hypersensitivity (DTH) response in the subject. This composition is particularly useful in treating epithelial tumors, such as warts or verrucae, that are induced by or related to papillomavirus. Antigens useful in the present pharmaceutical composition are anergy panel antigens, such as killed mumps virus, candida extract, trichophyton extract or comparable antigenic extracts. An additional pharmaceutical composition, also useful for treating epithelial tumors, contains at least one antigen that induces or is capable of inducing a cutaneous DTH response in a subject, at least one cytokine or colony stimulating factor and a pharmaceutically acceptable carrier. Kits containing these pharmaceutical compositions are useful for this immunotherapy.
REFERENCES:
patent: 5662903 (1997-09-01), Boyer et al.
patent: 6033673 (2000-03-01), Clements
patent: 6123948 (2000-09-01), Whittle et al.
patent: 2002/0009429 (2002-01-01), Bostwick
patent: WO 95/13089 (1995-05-01), None
Harada, S., The Japanese Journal of Dermatology (Nippon Hifuka Gakkai Zashi), 1979, vol. 89, pp. 397-402.
Heisser et al., Delayed type hypersensitivity (DTH) skin testing (SKT) for the evaluation of cellular immunity: Normal responses for adult men and women, Jan. 1996, p. 399 , Program and Abstracts of Papers to be Presented during Scientific Sessions 52nd Annual Meeting Journal of Allergy and Clinical Immunology, vol. 97, Issue 1, Part, 3.
Amer et al., “Therapeutic evaluation for intralesional injection of bleomyclin sulfate in 143 resistant warts,”J. Amer. Acad. Dermatol., 18(15):1313-6 (1988).
Baker et al., “Therapeutic Approaches to Papillomavirus Infections,”Infectious Diseases in Dermatology, 15(2):331-340 (1997).
Bolin,Equine Disease Quarterly, vol. 7, No. 3 (Apr. 1999).
Brodell et al., “The Treatment of Palmar and Plantar Warts Using Natural Alpha Interferon and a Needless Injector,”Dermatol Surg., 21:213-218 (1995) ® Elsevier Science, Inc.
Grier et al., “Regression of Cutaneous Melanosarcoma Following IntralesionslMycobacterium bovisBCG Injection: A Case Report,”J. of American Animal Hospital Association, 14:76-81 (1978).
Horn, Thomas, “Intradermal Skin Testing and Treatment withCandidaand Mumps Antigens of Verruca Vulgaris”, Dialog Abstract No. 121478 dated Jun. 25, 1998.
Johansson et al., “Dinitrochlorbenzene (DNCB) Treatment of Viral Warts,”Acta. Derm Venereol, 64:529-533 (1984).
Johnson et al., “Warts: A Guide to Their Removal,”Consultant39(1):253-266 (1999).
Klein et al., “Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial,”Cancer Immunol Immunother21:133-140 (1986)® Springer-Verlag.
Landow, Ken, “Nongenital warts, When is treatment warranted?,”Postgraduate Medicine, 99(3):245-249 (1996).
Miller, et al., “Human Papillomavirus Infection: Treatment Options for Warts,”American Family Physician53(1):135-143 (1996).
Miller et al., Ophthalmic Surg., vol. 25, No. 8, abstract only (1994).
Mond et al., Abstract of WO 95/13089 (1995).
Naples, et al., “Verruca Vulgaris: Treatment with Natural Interferon Alfa Using a Needleless Injector,”Arch Dermatol, 129:698-700 (1993).
Naylor et al., “Contact Immunotherapy of Resistant Warts,”J. Am Acad Dermatol, 19:679-83 (1988).
Nelson, Nancy, “Cancer Vaccines, Disappointing in the Past, Show Promise,”J. of the National Cancer Institute, 88(8):486-488 (1996).
Pfister et al., “Role of HPV in Cutaneous Premalignant and Malignant Tumors,”Clinics in Dermatology, 15:335-347 (1997) ® Elsevier Science Inc., New York, New York.
Quan et al., “The role of human papillomavirus in carcinoma,”J. Am Acad Dermatol., 25(4):698-705 (1991).
Parsad et al., “Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children,”Pediatric Dermatology(Jul.-Aug. 2001), vol. 18, No. 4, pp. 349-352, Abstract.
Aventis Pasteur, “Mumps Skin Test Antigen USP”, Product Information Brochure as of Feb. 1997, 2 pages.
Bellone et al. (Immunology Today, v20 (10), 1999, pp. 457-462).
Gaiger et al. (Blood, vol. 96, No. 4, Aug. 2000, pp. 1480-1489).
Johnson et al., “Intralesional Injection of Mumps orCandidaSkin Test Antigens; A Novel Immunotherapy for Warts,”Arch. Dermatol. (Apr. 2001), vol. 137, pp. 451-455.
Phillips et al., “Treatment of Warts withCandidaAntigen Injection,”Archives of Dermatology(Oct. 2001), full paper, 7 pages.
Phillips et al., “Treatment of Warts withCandidaAntigen Injection,”Arch. Dermatol. (Oct. 2000), vol. 136, pp. 1274-1275, Vignette.
Signore, Letter commenting on “CandidaImmunotherapy of Warts,”Arch. Dermatol. (Sep. 2001), vol. 137, pp. 1250-1251.
Harada, “Clinical application of fungus extracts and their culture filtrates in the treatment of skin diseases:Candidavaccine in the treatment of warts,”The Japanese Journal of Dermatology(Nippon Hifuka Gakkai Zashi) (1979), vol. 89, No. 6, pp. 397-402.
McConahy, “Common Warts: Immunity as a Result of Therapy,”CUTIS(Feb. 1976), vol. 17, pp. 301-304.
Greensher, “The Treatment of Warts with Mumps Skin Test Antigen,”Society of Teachers of Family Medicine, 9 pages.
Greensher, “Treatment of Laryngeal Papillomas with Mumps Skin Test Antigen,”The Lancet(Oct. 25, 1980), pp. 920-921.
Naylor et al., “Contact immunotherapy of resistant warts,”Journal of the American Academy of Dermatology(Oct. 1988), vol. 19, No. 4, pp. 679-683, Abstract.
Stedman's Medical Dictionary, 27th ed., 2000, Lippincott Williams, definition of “Antigen.”
Janeway, C. et al., Immunobiology: The Immune System in Health and Disease, 3rd ed., 1997, Curr. Biol. Ltd., London, Chapter 11.
Nieuwenhuis, P. pp. 3-32 in The Physiology of Immunity, J.A. Marsh et al. eds., 1996, CRC Press, Boca Raton, FL.
Alberts, B. et al., Molecular Biology of the Cell, 1983, Garland Publishing, New York, pp. 951-1012.
Miller et al. 1994. The conjunctival wart: report of a case and review of treatment and options.Ophthalmic Surg. 25: 545-548.
Briggaman R A, Wheeler C E. Immunology of human warts.J Am Acad Dermatol1979; 1:297-304.
Del Giudice, G, Pizza M, Rappuoli R. Molecular basis of vaccination.Molecular Aspects of Medicine1998;19(1):1-70.
Phillips et al. 2000. Treatment of warts withCandidaantigen injection.Arch. Dermatol. 136:1274-1275.
Signore. 2001Arch. Dermatol. 137:1250-1251.
McConahy. 1976. Common warts: immunity as a result of therapy. CUTIS 17: 301-304.
Greensher, A. 1980. Treatment of laryngeal papillomas with mumps skin test antigen.Lancet(Oct. 25, 1980) pp. 920-921.
Johnson et al., 2001, Intralesional injection of mumps orCandidaskin test antigens: a novel immunotherapy for warts.Arch. Dermatol. 137:451-455.
Morison, W. Cell-mediated immune responses in patients with warts.Br J Dermatol1975; 93:553-556.
Benton, E C. Therapy of epithelial warts.Clinics in Dermatology1997; 15:449-455.
Beutner, K R, Spruance S L, Hougham A J, Fox T L, Owens M L, Douglas J M. Treatment of genital warts with an immune-response modifier (imiquimod).J Am Acad Dermatol1998; 38:230-9.
Amer, M, Diab N, Ramadan A, Galal A, Salem A. Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts.J Am Acad Dermatol1988; 18:1313-6.
Adler A, Safai B. Immunity in wart resolution.J Am Acad Dermatol1979; 1:305-309.
Swinehart, J M, Skinner R B, McCarty J M, Miller B H, Tyring S K, Korey A, Orenberg E K. Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condyloma acuminata: two phase II clinical studies.Genitourin Med1997; 73:481-487.
Pfister H. Human papilomav
Horn Thomas Dag
Johnson Sandra Marchese
McTavish Hugh
The Board of Trustees of the University of Arkansas
Yu Misook
LandOfFree
Immunotherapy of epithelial tumors using intralesional... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapy of epithelial tumors using intralesional..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy of epithelial tumors using intralesional... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4235304